<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110954">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916265</url>
  </required_header>
  <id_info>
    <org_study_id>PCDiab01</org_study_id>
    <nct_id>NCT01916265</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages</brief_title>
  <official_title>A Randomised, Single Center, Three-period Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages at Four Different Blood Glucose Concentrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and
      glucagon) substituting for the pancreas and facilitating tight euglycemic control in
      patients with T1DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned as open, randomised 3-period cross-over in patients with T1DM. The
      study will include a total of 6 completing patients. The study is not blinded due to the
      exploratory nature.

      At each of the 3 periods, different blood glucose level will be established in 4 steps (8,
      6, 4, and 2.8 mmol/L), and a prefixed glucagon dose will be given per glucose level. The
      sequence of glucagon dose strength for the three dosing days will be randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>AUCGlucose of different glucagon dosages given s.c.</measure>
    <time_frame>90 min after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>Glucagon level: 0,11 and 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon level: 0,11 and 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon level: 0,22 and 0,66 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon level: 0,22 and 0,66 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon level: 0,44 and 0,33 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon level: 0,44 and 0,33 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <arm_group_label>Glucagon level: 0,11 and 1 mg</arm_group_label>
    <arm_group_label>Glucagon level: 0,22 and 0,66 mg</arm_group_label>
    <arm_group_label>Glucagon level: 0,44 and 0,33 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with diabetes mellitus type 1 , as defined by the American
             Diabetes Association1.

          -  Age ≥ 18 and ≤ 65 years.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product(s) or related products.

          -  Receipt of any investigational medicinal product within 3 months or 5 half-lives of
             that IMP before randomisation in this trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <state>NRW</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
